Nanomedsyn has described lysosome targeting chimeras (LYTACs) comprising cation-independent mannose-6-phosphate receptor (IGF-2R)-targeting glycosides covalently linked to TNF-α degradation inducers.

University of Debrecen researchers have prepared dehydroepiandrosterone (DHEA) derivatives reported to be useful for the treatment of atherosclerosis.

Recent Bristol Myers Squibb Co. patents describe new Toll-like receptor 9 (TLR9) antagonists reported to be useful for the treatment of inflammation, autoimmune disease, cancer, fibrosis, nonalcoholic steatohepatitis, chronic kidney disease, primary sclerosing cholangitis and idiopathic pulmonary fibrosis, among others.

Pivalent Therapeutics Inc. has reported the development of phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors.

ATP-dependent RNA helicase A (DHX9) inhibitors have been reported in an Accent Therapeutics Inc. patent as potentially useful for the treatment of cancer.

A Duke Street Bio Ltd. patent details new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

Researchers at Lucy Therapeutics Inc. have identified new adenosine receptor agonists...

PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...

Insilico Medicine IP Ltd. has synthesized membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.